Repligen price target raised to $175 from $160 at Barclays

Barclays raised the firm’s price target on Repligen (RGEN) to $175 from $160 and keeps an Overweight rating on the shares following the earnings report. The company’s outlook downshift or next year is driven by a lower market growth outlook based on peer commentary, but there is potential upside, the analyst tells investors in a research note.